Through an agreement with the Puerto Rico Industrial Development Co. (PRIDCo), Actavis is investing $48 million in a solid dosage manufacturing and packing facility at its Manati site and will expand its current hormone production in Fajardo.
The expansion will create as many as 300 new jobs during a three-year period. The company also recently acquired the global operations of Warner Chilcott, including the Manati and Fajardo plants. The investment will allow the company to bring new lines of generic, brand and biosimilar products.
PRIDCo is promoting the expansion with incentives for job creation and infrastructure, as well as other benefits under the Economic Incentives for Development Act.
“This is a significant increase in production and jobs of a company that already is contributing close to $78 million a year to Puerto Rico’s economy, between salaries, income taxes and purchases to suppliers,” said governor García Padilla while visiting the Manati site, on the northern region of PR.
The expansion will create as many as 300 new jobs during a three-year period. The company also recently acquired the global operations of Warner Chilcott, including the Manati and Fajardo plants. The investment will allow the company to bring new lines of generic, brand and biosimilar products.
PRIDCo is promoting the expansion with incentives for job creation and infrastructure, as well as other benefits under the Economic Incentives for Development Act.
“This is a significant increase in production and jobs of a company that already is contributing close to $78 million a year to Puerto Rico’s economy, between salaries, income taxes and purchases to suppliers,” said governor García Padilla while visiting the Manati site, on the northern region of PR.
